Literature DB >> 8034635

Proglucagon processing in porcine and human pancreas.

J J Holst1, M Bersani, A H Johnsen, H Kofod, B Hartmann, C Orskov.   

Abstract

In the pancreas proglucagon (PG), a peptide precursor of 160 amino acids is cleaved to produce glucagon and a 30-amino acid N-terminal flanking peptide, but the fate of the C-terminal flanking peptide (99 amino acids) is incompletely known. We subjected acid ethanol extracts of human and porcine pancreases to gel filtration and analyzed the fractions with specific radioimmunoassays for the following regions of proglucagon: PG 62-69, PG 72-81, PG 78-87, PG 98-107 amide, PG 126-134, and PG 149-158. Based on these assays and successive purifications by high performance liquid chromatography we isolated and purified to homogeneity three porcine peptides which were subjected to mass spectrometry and sequencing. One peptide was PG 64-69. The second was PG 72-108, as determined by mass spectrometry, N-terminal amino acid sequencing, and specific radioimmunoassays. The third had a molecular size of approximately 10,000, an N-terminal sequence corresponding to PG 72-81, and a C-terminal sequence terminating at PG 158 (specific radioimmunoassay). A similar peptide with an identical N-terminal sequence, a C-terminal sequence corresponding to PG 146-158, and a molecular mass of 9969 (theoretical mass for human PG 72-158 = 9971) was isolated from human pancreas together with small amounts of a peptide corresponding to PG 72-107 amide. Thus, the pancreatic processing of the C-terminal flanking peptide in proglucagon includes the formation of equimolar (to glucagon) amounts of PG 64-69 and PG 72-158 (major proglucagon fragment) and smaller amounts of N-terminally extended glucagon-like peptide-1 (GLP-1) (PG 72-108 in pigs and PG 72-107 amide in humans).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8034635

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

Review 1.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

2.  A model of GLP-1 action on insulin secretion in nondiabetic subjects.

Authors:  Chiara Dalla Man; Francesco Micheletto; Airani Sathananthan; Robert A Rizza; Adrian Vella; Claudio Cobelli
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-02-23       Impact factor: 4.310

Review 3.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

4.  Mechanism of action of DPP-4 inhibitors--new insights.

Authors:  Adrian Vella
Journal:  J Clin Endocrinol Metab       Date:  2012-08       Impact factor: 5.958

5.  Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2.

Authors:  M Furuta; H Yano; A Zhou; Y Rouillé; J J Holst; R Carroll; M Ravazzola; L Orci; H Furuta; D F Steiner
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

Review 6.  Growth factor control of pancreatic islet regeneration and function.

Authors:  Anke Assmann; Charlotte Hinault; Rohit N Kulkarni
Journal:  Pediatr Diabetes       Date:  2008-09-19       Impact factor: 4.866

7.  New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins.

Authors:  Baptist Gallwitz
Journal:  Rev Diabet Stud       Date:  2005-08-10

8.  A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets.

Authors:  P Marchetti; R Lupi; M Bugliani; C L Kirkpatrick; G Sebastiani; F A Grieco; S Del Guerra; V D'Aleo; S Piro; L Marselli; U Boggi; F Filipponi; L Tinti; L Salvini; C B Wollheim; F Purrello; F Dotta
Journal:  Diabetologia       Date:  2012-09-11       Impact factor: 10.122

9.  Glucagon-like peptide-1(7-37) has a larger volume of distribution than glucagon-like peptide-1(7-36)amide in dogs and is degraded more quickly in vitro by dog plasma.

Authors:  L Pridal; C F Deacon; O Kirk; J V Christensen; R D Carr; J J Holst
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Jan-Mar       Impact factor: 2.441

Review 10.  Do glucagonomas always produce glucagon?

Authors:  Nicolai Jacob Wewer Albrechtsen; Benjamin G Challis; Ivan Damjanov; Jens Juul Holst
Journal:  Bosn J Basic Med Sci       Date:  2016-02-01       Impact factor: 3.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.